ANCA-associated rapidly progressive glomerulonephritis in a patient with IgA nephropathy, case report.
PDF (Español (España))
PDF

Supplementary Files

Carta de presentación (Español (España))

Keywords

IgA nephropathy
rapidly progressive glomerulonephritis
vasculitis
ANCA
crescents.

How to Cite

1.
Peña Wilches A, Arias Agudelo J de J, Ossa Gómez LJ, Gutiérrez González D, Echeverri Sarmiento JE, Larrarte Arenas C. ANCA-associated rapidly progressive glomerulonephritis in a patient with IgA nephropathy, case report. Rev. Colomb. Nefrol. [Internet]. 2017 Jul. 27 [cited 2021 Dec. 7];4(2):200-9. Available from: https://www.revistanefrologia.org/index.php/rcn/article/view/272

Abstract

IgA nephropathy is the most common glomerulonephritis, in which less than 10% of patients have a rapid decline of renal function. The histological findings of this group
resemble those of vasculitis, with presence of crescents and fibrinoid necrosis. The coexistence of IgA nephropathy and neutrophil anti-cytoplasmic antibodies is infrequent, and the pathogenic role of these antibodies in IgA nephropathy is unclear. Here we describe a case of a patient with IgA nephropathy, rapidly progressive glomerulonephritis and neutrophil positive anti-cytoplasmic antibodies, and literature review is presented.

https://doi.org/10.22265/acnef.4.2.272
PDF (Español (España))
PDF

References

1. Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol. 2000;11(12):2395-403.

2. Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18(5):503-12.

3. Rojas-Rivera J, Fernandez-Juarez G, Praga M. Rapidly progressive IgA nephropathy: a form of vasculitis or a complement-mediated disease? Clin Kidney J. 2015;8(5):477-481. Disponible en: https://doi.org/10.1093ckj/sfv095

4. Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D, et al. Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis.2010;55(2):259-68. Disponible en: https://doi.org/10.1053j.ajkd.2009.09.031

5. Huang X, Wang Y, Xie L, Zhang Y, Tang S, Yin S, et al. IgA nephropathy with anti-neutrophil cytoplasmic antibody seropositivity.Clin Nephrol. 2015;84(3):156-64. Disponible en: https://doi.org/10.5414/CN108571

6. Ozaltin F, Bakkaloglu A, Ozen S, Topaloglu R, Kavak U, Kalyoncu M, et al. The significance of IgA class of antineutrophil cytoplasmic antibodies (ANCA) in childhood Henoch-Schönlein purpura. Clin Rheumatol. 2004;23(5):426-9. Disponible en: https://doi.org/10.1007s10067-004-0910-y

7. Ronda N, Esnault VL, Layward L, Sepe V, Allen A, Feehally J, et al. Antineutrophil cytoplasm antibodies (ANCA) of IgA isotype in adult Henoch-Schönlein purpura. Clin Exp Immunol. 1994;95(1):49-55. Disponible en: https://doi.org/10.1111/j.1365-2249.1994.tb06013.x

8. Ara J, Bonet J, Rodríguez R, Mirapeix E, Agraz I, Romero R. IgA nephropathy with crescentic glomerulonephritis and ANCA positive. Nefrologia. 2005;25(6): 712-7.

9. Martin SJ, Audrain MA, Baranger T, Moreau A, Dantal J, Testa A, et al. Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation. Am J Kidney Dis. 1997;29(1):125-31.Disponible en: https://doi.org10.1016/S0272-6386(97)90019-6

10. Bollee G, Noel LH, Suarez F, Royal V, Gilardin L, de Serre NP, et al. auci-immune crescentic glomerulonephritis associated with ANCA of IgA class. Am J Kidney Dis. 2009;53(6):1063-7. Disponible en: https://doi.org10.1053/j.ajkd.2008.10.039

11. O’Donoghue DJ, Nusbaum P, Noel LH, Halbwachs-Mecarelli L, Lesavre P. Antineutrophil cytoplasmic antibodies in IgA nephropathy and Henoch-Schönlein purpura. Nephrol Dial Transplant. 1992;7(6):534-8.

12. Allmaras E, Nowack R, Andrassy K, Waldherr R, van der Woude F, Ritz E. Rapidly progressive IgA nephropathy with anti-myeloperoxidase antibodies benefits from immunosuppression. Clin Nephrol. 1997;48(5):269-73.

13. Ramirez SB, Rosen S, Niles J, Somers MJ. IgG antineutrophil cytoplasmic antibodies in IgA nephropathy: a clinical variant? Am J Kidney Dis. 1998;31(2):341-4. Disponible en: https://doi.org/10.1053ajkd.1998.v31.pm9469508

14. Haas M, Jafri J, Bartosh SM, Karp SL, Adler SG, Meehan SM. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Am J Kidney Dis. 2000;36(4):709-18. Disponible en: https://doi.org10.1053/ajkd.2000.17615

15. Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D, et al. Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis. 2010;55(2):259-68. Disponible en: https://doi.org/10.1053j.ajkd.2009.09.031

16. Yang YZ, Shi SF, Chen YQ, Chen M, Yang YH, Xie XF, et al. Clinical features of IgA nephropathy with serum ANCA positivity:a retrospective case-control study. Clin Kidney J. 2015;8(5):482-8. Disponible en:https://doi.org/10.1093/ckj/sfv078

17. Lv J, Yang Y, Zhang H, Chen W, Pan X, Guo Z, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013;24(12):2118-25. Disponible en: https://doi.org10.1681/ASN.2012101017

18. Tumlin JA, Hennigar RA. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. Semin Nephrol.2004;24(3):256-68. Disponible en: https://doi.org/10.1016j.semnephrol.2004.01.006

19. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):139-274. Chapter 10, Immunoglobulin A nephropathy; p. 209-17. Disponible en: https://doi.org/10.1038/kisup.2012.23

20. Xie X, Lv J, Shi S, Zhu L, Liu L, Chen M, et al. Plasma Exchange as an Adjunctive Therapy for Crescentic IgA Nephropathy. Am J Nephrol. 2016;44(2):141-9. https://doi.org/10.1159/000448767

21. Espinosa M, Ortega R, Sanchez M, Segarra A, Salcedo MT, Gonzalez F, et al; Spanish Group for Study of Glomerular Diseases (GLOSEN). Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2014;9(5): 897-904. Disponible en: https://doi.org/10.2215/CJN.09710913

22. Gherghiceanu M, Penescu M, Mandache E. The predictive value of peritubular capillaries C3d deposition in IgA glomerulonephritis. J Cell Mol Med. 2005;9(1):143-52. Disponible en: https://doi.org/10.1111j.1582-4934.2005.tb00344.x

23. Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I, et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol.2015;30(1):167-72. Disponible en: https://doi.org/10.1007/s00467-014-2944-y

24. Jayne DRW, Bruchfeld A, Schaier M, Ciechanowski K, Harper L, Jadoul M, et al. Glomerulonephritides. Phase 2 randomised trial of oral C5a receptor antagonist CCX168 in ANCAassociated renal vasculitis. Nephrol Dial Transplant. 2014;29(Suppl 3):iii27–9. Disponible en: https://doi.org/10.1093/ndt/gfu120

25. Ring T, Pedersen BB, Salkus G, Goodship TH. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J. 2015;8(5):489-91. Disponible en: https://doi.org/10.1093ckj/sfv076
No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.

Downloads

Download data is not yet available.